{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T22:54:38Z","timestamp":1776466478151,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"crossref","award":["No. 2023AFB807"],"award-info":[{"award-number":["No. 2023AFB807"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 92268108"],"award-info":[{"award-number":["No. 92268108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06767-3","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:19:36Z","timestamp":1751429976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Dongke","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruohang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaofan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"24","key":"6767_CR1","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1001\/jama.2020.21360","volume":"324","author":"J Maret-Ouda","year":"2020","unstructured":"Maret-Ouda, J., Markar, S. R. & Lagergren, J. Gastroesophageal Reflux Disease: A Review. JAMA 324(24), 2536\u20132547 (2020).","journal-title":"JAMA"},{"issue":"4","key":"6767_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cgh.2008.11.021","volume":"7","author":"LB Gerson","year":"2009","unstructured":"Gerson, L. B. & Fass, R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin. Gastroenterol. Hepatol. 7(4), 372\u2013367 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"6767_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/j.1572-0241.2003.07531.x","volume":"98","author":"R Shaker","year":"2003","unstructured":"Shaker, R., Castell, D. O., Schoenfeld, P. S. & Spechler, S. J. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am. J. Gastroenterol. 98(7), 1487\u20131493 (2003).","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"6767_CR4","first-page":"509","volume":"89","author":"WC Orr","year":"1994","unstructured":"Orr, W. C., Allen, M. L. & Robinson, M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am. J. Gastroenterol. 89(4), 509\u2013512 (1994).","journal-title":"Am. J. Gastroenterol."},{"issue":"11","key":"6767_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199903183401101","volume":"340","author":"J Lagergren","year":"1999","unstructured":"Lagergren, J., Bergstr\u00f6m, R., Lindgren, A. & Nyr\u00e9n, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340(11), 825\u2013831 (1999).","journal-title":"N. Engl. J. Med."},{"key":"6767_CR6","doi-asserted-by":"crossref","unstructured":"Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review [published correction appears in Clin Gastroenterol Hepatol. 2022 Sep;20(9):2156].\u00a0Clin. Gastroenterol Hepatol.. (2022).","DOI":"10.1016\/j.cgh.2022.01.025"},{"issue":"5","key":"6767_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2036.2009.04064.x","volume":"30","author":"DA Peura","year":"2009","unstructured":"Peura, D. A., Riff, D. S., Snoddy, A. M. & Fennerty, M. B. Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol. Ther. 30(5), 459\u2013468 (2009).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"2","key":"6767_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1365-2036.2010.04339.x","volume":"32","author":"D Johnson","year":"2010","unstructured":"Johnson, D., Crawley, J. A., Hwang, C. & Brown, K. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances. Aliment Pharmacol. Ther. 32(2), 182\u2013190 (2010).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"12","key":"6767_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/j.1365-2036.2009.04013.x","volume":"29","author":"R Fass","year":"2009","unstructured":"Fass, R. et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol. Ther. 29(12), 1261\u20131272 (2009).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"3","key":"6767_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/ajg.2010.458","volume":"106","author":"R Fass","year":"2011","unstructured":"Fass, R. et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am. J. Gastroenterol. 106(3), 421\u2013431 (2011).","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"6767_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1046\/j.1365-2036.2002.t01-1-01281.x","volume":"16","author":"UC Nzeako","year":"2002","unstructured":"Nzeako, U. C. & Murray, J. A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol. Ther. 16(7), 1309\u20131316 (2002).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"12","key":"6767_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1046\/j.1365-2036.1998.00419.x","volume":"12","author":"PO Katz","year":"1998","unstructured":"Katz, P. O., Anderson, C., Khoury, R. & Castell, D. O. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol. Ther. 12(12), 1231\u20131234 (1998).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"4","key":"6767_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1046\/j.1365-2036.2002.01229.x","volume":"16","author":"N Shirai","year":"2002","unstructured":"Shirai, N. et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol. Ther. 16(4), 837\u2013846 (2002).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"2","key":"6767_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1152\/physrev.00016.2019","volume":"100","author":"AC Engevik","year":"2020","unstructured":"Engevik, A. C., Kaji, I. & Goldenring, J. R. The Physiology of the Gastric Parietal Cell. Physiol. Rev. 100(2), 573\u2013602 (2020).","journal-title":"Physiol. Rev."},{"issue":"10","key":"6767_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/gut.24.10.904","volume":"24","author":"T Gledhill","year":"1983","unstructured":"Gledhill, T., Howard, O. M., Buck, M., Paul, A. & Hunt, R. H. Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer. Gut 24(10), 904\u2013908 (1983).","journal-title":"Gut"},{"issue":"3","key":"6767_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1053\/gast.2002.31876","volume":"122","author":"WK Fackler","year":"2002","unstructured":"Fackler, W. K., Ours, T. M., Vaezi, M. F. & Richter, J. E. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122(3), 625\u2013632 (2002).","journal-title":"Gastroenterology"},{"issue":"9","key":"6767_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1046\/j.1365-2036.2001.01050.x","volume":"15","author":"S Xue","year":"2001","unstructured":"Xue, S., Katz, P. O., Banerjee, P., Tutuian, R. & Castell, D. O. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol. Ther. 15(9), 1351\u20131356 (2001).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"6","key":"6767_CR18","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s10620-014-3489-4","volume":"60","author":"EH Kim","year":"2015","unstructured":"Kim, E. H. et al. Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. Dig. Dis. Sci. 60(6), 1724\u20131732 (2015).","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"6767_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00535-010-0283-8","volume":"45","author":"S Ohara","year":"2010","unstructured":"Ohara, S., Haruma, K., Kinoshita, Y. & Kusano, M. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J. Gastroenterol. 45(12), 1219\u20131227 (2010).","journal-title":"J. Gastroenterol."},{"key":"6767_CR20","doi-asserted-by":"crossref","unstructured":"Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0.\u00a0Neurogastroenterol Motil. 27(2):160\u2013174. (2015).","DOI":"10.1111\/nmo.12477"},{"issue":"4","key":"6767_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5056\/jnm21077","volume":"27","author":"HK Jung","year":"2021","unstructured":"Jung, H. K. et al. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J. Neurogastroenterol Motil. 27(4), 453\u2013481 (2021).","journal-title":"J. Neurogastroenterol Motil."},{"key":"6767_CR22","doi-asserted-by":"crossref","unstructured":"Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 73(2):361\u2013371. (2024).","DOI":"10.1136\/gutjnl-2023-330616"},{"issue":"2","key":"6767_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4292\/wjgpt.v5.i2.57","volume":"5","author":"JW McRorie","year":"2014","unstructured":"McRorie, J. W., Kirby, J. A. & Miner, P. B. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J. Gastrointest Pharmacol. Ther. 5(2), 57\u201362 (2014).","journal-title":"World J. Gastrointest Pharmacol. Ther."},{"issue":"6","key":"6767_CR24","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai, Y. et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol. Ther. 42(6), 719\u2013730 (2015).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"1","key":"6767_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00228-017-2324-1","volume":"74","author":"T Suzuki","year":"2018","unstructured":"Suzuki, T. et al. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur. J. Clin. Pharmacol. 74(1), 45\u201352 (2018).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"6767_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/apt.15641","volume":"51","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi, T. et al. Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol. Ther. 51(5), 534\u2013543 (2020).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"6","key":"6767_CR27","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cgh.2024.01.037","volume":"22","author":"J Arai","year":"2024","unstructured":"Arai, J. et al. Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication. Clin. Gastroenterol. Hepatol. 22(6), 1217-1225.e6 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"6767_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","volume":"167","author":"A Patel","year":"2024","unstructured":"Patel, A. et al. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology 167(6), 1228\u20131238 (2024).","journal-title":"Gastroenterology"},{"issue":"3","key":"6767_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1572-0241.2003.07304.x","volume":"98","author":"TM Ours","year":"2003","unstructured":"Ours, T. M., Fackler, W. K., Richter, J. E. & Vaezi, M. F. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am. J. Gastroenterol. 98(3), 545\u2013550 (2003).","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"6767_CR30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1080\/00365520701864635","volume":"43","author":"UC Ghoshal","year":"2008","unstructured":"Ghoshal, U. C., Chourasia, D., Tripathi, S., Misra, A. & Singh, K. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry. Scand J. Gastroenterol. 43(6), 654\u2013661 (2008).","journal-title":"Scand J. Gastroenterol."},{"issue":"1","key":"6767_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000210107","volume":"27","author":"J Weigt","year":"2009","unstructured":"Weigt, J., Kandulski, A., B\u00fcsch, F. & Malfertheiner, P. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients. Dig. Dis. 27(1), 68\u201373 (2009).","journal-title":"Dig. Dis."},{"issue":"2","key":"6767_CR32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5056\/jnm16087","volume":"23","author":"A Karyampudi","year":"2017","unstructured":"Karyampudi, A. et al. Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease. J. Neurogastroenterol. Motil. 23(2), 208\u2013217 (2017).","journal-title":"J. Neurogastroenterol. Motil."},{"issue":"6","key":"6767_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1442-2050.2005.00518.x","volume":"18","author":"A Rackoff","year":"2005","unstructured":"Rackoff, A. et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis. Esophagus. 18(6), 370\u2013373 (2005).","journal-title":"Dis. Esophagus."},{"issue":"12","key":"6767_CR34","doi-asserted-by":"publisher","first-page":"e14385","DOI":"10.1111\/nmo.14385","volume":"34","author":"JM Schuitenmaker","year":"2022","unstructured":"Schuitenmaker, J. M., Kuipers, T., Smout, A. J. P. M., Fockens, P. & Bredenoord, A. J. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux. Neurogastroenterol. Motil. 34(12), e14385 (2022).","journal-title":"Neurogastroenterol. Motil."},{"issue":"6","key":"6767_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.21037\/apm-23-90","volume":"12","author":"K Cho","year":"2023","unstructured":"Cho, K. et al. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer. Ann. Palliat Med. 12(6), 1136\u20131145 (2023).","journal-title":"Ann. Palliat Med."},{"issue":"13","key":"6767_CR36","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1073\/pnas.1337252100","volume":"100","author":"M Numazaki","year":"2003","unstructured":"Numazaki, M. et al. Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc. Natl. Acad. Sci. U S A. 100(13), 8002\u20138006 (2003).","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"12","key":"6767_CR37","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.3390\/molecules28124736","volume":"28","author":"L Liu","year":"2023","unstructured":"Liu, L. & Tian, Y. Capsaicin Changes the Pattern of Brain Rhythms in Sleeping Rats. Molecules 28(12), 4736 (2023).","journal-title":"Molecules"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06767-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06767-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06767-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:19:38Z","timestamp":1751429978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06767-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6767"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06767-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23286"}}